Kinnate Biopharma Inc. (NASDAQ:KNTE – Get Free Report) has been assigned an average recommendation of “Hold” from the five brokerages that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $8.15.
A number of research analysts have commented on the company. William Blair downgraded Kinnate Biopharma from an “outperform” rating to a “market perform” rating in a research note on Friday, February 16th. Wedbush restated a “neutral” rating and issued a $2.00 price objective on shares of Kinnate Biopharma in a report on Wednesday, January 17th. Finally, Stifel Nicolaus lifted their target price on shares of Kinnate Biopharma to $2.59 and gave the company a “hold” rating in a research note on Monday, February 26th.
Read Our Latest Analysis on KNTE
Kinnate Biopharma Trading Down 0.4 %
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in KNTE. Deltec Asset Management LLC bought a new stake in Kinnate Biopharma during the first quarter worth approximately $2,766,000. BML Capital Management LLC acquired a new stake in shares of Kinnate Biopharma in the fourth quarter worth $1,110,000. Citigroup Inc. lifted its stake in shares of Kinnate Biopharma by 53,138.6% in the third quarter. Citigroup Inc. now owns 420,585 shares of the company’s stock worth $589,000 after buying an additional 419,795 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Kinnate Biopharma by 71.0% during the 3rd quarter. Acadian Asset Management LLC now owns 736,686 shares of the company’s stock worth $1,030,000 after buying an additional 305,884 shares during the period. Finally, Acuitas Investments LLC acquired a new position in Kinnate Biopharma in the 4th quarter valued at $687,000. Institutional investors and hedge funds own 80.89% of the company’s stock.
Kinnate Biopharma Company Profile
Kinnate Biopharma Inc, a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program.
Featured Articles
- Five stocks we like better than Kinnate Biopharma
- Energy and Oil Stocks Explained
- Hasbro’s Management Made All the Right Calls This Quarter
- Dividend Capture Strategy: What You Need to Know
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Kinnate Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kinnate Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.